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Oppermann M, Hansen PB, Castrop H, Schnermann J. Vaso-
dilatation of afferent arterioles and paradoxical increase of renal
vascular resistance by furosemide in mice. Am J Physiol Renal
Physiol 293: F279–F287, 2007. First published May 9, 2007;
doi:10.1152/ajprenal.00073.2007.—Loop diuretics like furosemide
have been shown to cause renal vasodilatation in dogs and humans, an
effect thought to result from both a direct vascular dilator effect and
from inhibition of tubuloglomerular feedback. In isolated perfused
afferent arterioles preconstricted with angiotensin II or NG-nitro-L-
arginine methyl ester, furosemide caused a dose-dependent increase of
vascular diameter, but it was without effect in vessels from
NKCC1/ mice suggesting that inhibition of NKCC1 mediates
dilatation in afferent arterioles. In the intact kidney, however, furo-
semide (2 mg/kg iv) caused a 50.5 3% reduction of total renal blood
flow (RBF) and a 27% reduction of superficial blood flow (SBF)
accompanied by a marked and immediate increase of tubular pressure
and volume. At 10 mg/kg, furosemide reduced RBF by 60.4  2%.
Similarly, NKCC1/ mice responded to furosemide with a 45.4%
decrease of RBF and a 29% decrease of SBF. Decreases in RBF and
SBF and increases of tubular pressure by furosemide were amelio-
rated by renal decapsulation. In addition, pretreatment with candesar-
tan (2 mg/kg) or indomethacin (5 mg/kg) attenuated the reduction of
RBF and peak urine flows caused by furosemide. Our data indicate
that furosemide, despite its direct vasodilator potential in isolated
afferent arterioles, causes a marked increase in flow resistance of the
vascular bed of the intact mouse kidney. We suggest that generation
of angiotensin II and/or a vasoconstrictor prostaglandin combined
with compression of peritubular capillaries by the expanding tubular
compartment are responsible for the reduction of RBF in vivo.
renal blood flow; superficial blood flow; candesartan; decapsulation;
tubular pressure; NKCC1 knockout
LOOP DIURETICS LIKE FUROSEMIDE or bumetanide are widely used
antihypertensive and diuretic drugs. Diuresis and loss of ex-
tracellular fluid result from an inhibitory interaction of the
diuretics with the Na-K-2Cl cotransporter NKCC2, the major
NaCl uptake pathway across the apical membrane of the thick
ascending limb (TAL). In addition, loop diuretics also inhibit
NKCC1, the second isoform of the Na-K-2Cl cotransporter
that is more widely expressed than NKCC2 (11). In polarized
cells, NKCC1 is typically located in the basolateral membrane,
and NKCC1-mediated NaCl uptake therefore is an early step in
transepithelial NaCl secretion. In nonpolarized cells, NKCC1
is believed to play a role in cell volume regulation and
maintenance of membrane potential. NKCC1 is widely ex-
pressed in the vasculature, and inhibition of this transporter
may account for direct vascular effects of loop diuretics that
appear to be vasodilatory in most vascular beds (8). The
interaction between the diuretics and the two different trans-
porter isoforms occurs with similar affinity (12). The appar-
ently preferential renal effect is presumably due to the fact that
the diuretics are secreted into the tubular lumen and concen-
trated so that higher concentrations are reached in the tubular
lumen than in the plasma.
The well-described actions of NKCC cotransporters would
suggest that the hemodynamic effect of loop diuretics in the
kidney should consist of vasodilatation. In addition to a pos-
sible direct renal vascular dilator effect of NKCC1 inhibition,
a reduction of renal vascular resistance should result from the
removal of the tonic constrictor effect exerted by the tubulo-
glomerular feedback (TGF) mechanism (40). Nevertheless, the
experimental data on the renal vascular effects of loop diuretics
are conflicting and difficult to reconcile, particularly when
comparing results from different species. The expected in-
crease of renal blood flow (RBF) has in fact been observed
in several studies in humans (34) and dogs (10, 26, 30). In
contrast, in the majority of studies in the rat, furosemide has
been found to cause an10–20% reduction of RBF (6, 15, 31,
32, 35, 44), although a hemodynamically neutral outcome has
also been reported (17, 41). When they occur, the renal hemo-
dynamic effects of NKCC inhibition in the rat appear to be
unrelated to the primary actions of the diuretic on tubular and
vascular functions. Rather, they may be dominated by second-
ary effects on RBF that are activated by the diuretic and may
be related to the size of the kidneys. In addition, loop diuretics
are known to rapidly stimulate renin secretion (3), and to
stimulate prostaglandin formation so that differences in the
response of these regulatory systems to the diuretic could cause
species-specific responses (38).
The present studies were performed in mice to assess the net
effect of furosemide on total renal and superficial renal vascu-
lar resistance in a species that is closer in size to rats than it is
to dogs or humans, and to compare the global effect of
furosemide with that observed in isolated renal resistance
vessels. Our studies show that furosemide causes a robust,
highly reproducible, and dose-dependent increase of renal
vascular resistance in wild-type mice that is qualitatively sim-
ilar to, but quantitatively more pronounced, than that previ-
ously observed in rats (6, 15, 31). Elevation of renal vascular
resistance occurred despite the fact that the loop diuretic elicits
direct vasodilatation of afferent arterioles through inhibition of
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NKCC1. Our data indicate that the mechanisms responsible for
the resistance increase in vivo are probably multifactorial.
Since angiotensin II receptor blockade and cyclooxygenase
inhibition diminished the blood flow reduction caused by
furosemide, direct or indirect effects of angiotensin and of a
vasoconstrictor prostaglandin may play a role. In addition,
removal of the kidney capsule attenuated the furosemide effect
indicating that compression of peritubular capillaries by the
expanding tubular compartment may contribute to the reduc-
tion in blood flow, an effect that may be more pronounced in
the smaller kidney of the mouse.
METHODS
Animals. Male wild-type mice used in these studies had a
mixed 129J/C57BL6 genetic background. Male NKCC1/ and
NKCC1/ mice from a subcolony of the original strain generated
by Flagella et al. (9) were generously supplied by Dr. S. Wall from
Emory University. All mice were kept on standard rodent chow and
tap water. Animal care and experimentation were approved and
carried out in accordance with National Institutes of Health principles
as outlined in their Guide for the Care and Use of Laboratory
Animals.
Animal preparation. Mice were anesthetized with 100 mg/kg thio-
butabarbital (inactin) intraperitoneally and 100 mg/kg ketamine sub-
cutaneously. Body temperature was maintained at 38.0°C by placing
the animals on an operating table with a servo-controlled heating
plate. The trachea was cannulated, and a stream of 100% oxygen was
blown toward the tracheal tube throughout the experiment. The left
femoral artery was catheterized with hand-drawn polyethylene tubing
for continuous measurement of arterial blood pressure. A catheter was
also inserted into the right jugular vein for an intravenous mainte-
nance infusion of saline at a rate of 12 l g body wt1 h1. The
bladder was catheterized for urine collections.
Measurements of total RBF and superficial renal blood flow. For
measurements of total RBF, the right renal artery was approached
from a flank incision and carefully dissected free to permit placement
of an ultrasonic flow probe (0.5PSB nanoprobe) connected to a TS402
perivascular flowmeter module (Transonic Systems, Ithaca, NY).
Superficial renal blood flow (SBF) was measured in the same mice
simultaneously using a real-time laser Doppler perfusion probe (418-2
Master Probe) with a straight microtip (B500). The probe was placed
on the renal surface and connected to a PF 5010 LDPM flowmeter
Unit/Periflux System 5000 (Perimed AB, Ja¨rfa¨lla, Sweden). Measure-
ments of SBF are expressed as arbitrary perfusion units (PU). Both
probes were held in place with micromanipulators. RBF and SBF
signals were digitized and analyzed using PowerLab software (AD-
Instruments, Colorado Springs, CO). Mean arterial blood pressure was
divided by RBF or SBF to obtain renal vascular resistance (RVR) or
superficial vascular resistance (SVR).
Experimental protocols. 1) After achieving stability in the RBF and
SBF recordings, furosemide (2 mg/kg; 1 l/g body wt; Sigma,
St. Louis, MO) was given as an intravenous bolus injection and
recordings were made over a period of 30 min; in another series of
five animals, furosemide was given at 10 mg/kg; 2) bolus injection of
the AT1 (angiotensin II type 1) receptor antagonist candesartan
(CV-11974; 2 mg/kg iv) followed by the injection of 2 mg/kg
furosemide; 3) removal of the kidney capsule (decapsulation) fol-
lowed by 2 mg/kg furosemide; 4) furosemide administration (2
mg/kg) after both candesartan and removal of the kidney capsule; 5)
administration of indomethacin (5 mg/kg) followed 5 min later by 2
mg/kg furosemide.
Micropuncture experiments. For measurements of proximal tubule
free flow pressure, the left kidney was approached from a flank
incision, freed of adherent fat and connective tissue, placed in a lucite
cup, and covered with mineral oil. Pressures were measured before
and for 30 min after furosemide injection (2 mg/kg body wt) using a
servo-null micropressure device (WPI, Sarasota, FL) and a digital
recording system (PowerLab, ADI Instruments).
Isolation and microperfusion of renal afferent arterioles. To deter-
mine the direct in vitro effect of furosemide at the arteriolar level,
afferent arterioles with attached glomeruli from male NKCC1/
and NKCC1/ mice (24–28 g) were isolated and microperfused.
The method was a modification of that used by Jensen et al. (16) and
Weihprecht et al. (39), and its adaptation to mouse arterioles has
recently been described in detail (13). After preconstriction of the
afferent arteriole by addition of 0.5 nM angiotensin II to the bath for
3 min, furosemide was added to the bath at increasing concentrations
(30 M, 300 M, 1.5 mM). As a control experiment, the effect of
angiotensin II during prolonged exposure was examined. Angiotensin
II 0.5 nmol/l was applied to the bath and the luminal diameter was
determined after 1, 3, 5, and 10 min. In another set of experiments, the
involvement of nitric oxide (NO) in the furosemide-mediated vasodi-
latation was investigated. The arterioles were exposed to the NO
synthase (NOS) antagonist N-nitro-L-arginine methyl ester
(L-NAME; 50 M; Sigma) for 20 min before furosemide (1.5 mmol/l)
was added to the bath in the continued presence of L-NAME. The
ability of 100 mM K to elicit constriction was tested after all
experiments.
Statistical analysis. Unpaired t-test was used to compare two values
between different groups. Integration as the area under the curve over
the 30-min time interval was conducted using GraphPad Prism.
Multiple groups were analyzed with ANOVA followed by Bonferroni
posttest. A P value 0.05 was considered significant.
RESULTS
Effect of furosemide on total and superficial blood flow. As
shown in an exemplary recording in Fig. 1, an intravenous
injection of furosemide (2 mg/kg body wt) caused an acute
reduction of total (RBF) and superficial RBF in anesthetized
mice without a concomitant reduction of blood pressure. On
average, RBF decreased from a baseline of 1.67  0.10 to
1.25  0.11 ml/min within 1 min and reaching a minimum of
0.83  0.07 ml/min after 10 min (Fig. 2), a decrease of 50.5 
2.8% from the baseline value (n  8). Similarly, SBF de-
creased from a baseline of 340  15 PU to a minimum of
250  18 PU after 15 min, a decrease of 27.0  2.8% (n  6).
Arterial blood pressure tended to increase slightly after furo-
semide injection, but at no time point was there a significant
elevation vs. baseline when tested by repeated-measures
ANOVA. At times above 10 min, arterial pressure fell in all
study groups. On average, there was a maximal increase in
RVR of 123.3  11.6% and a maximal increase of SVR of
52.4  6.2% (Table 1). Furosemide increased urinary flow
from 1.41  0.14 l/min to a maximum of 25.6  2.3 l/min
after 20 min. Blood pressure started to decrease after 20 min
coincident with the peak in urine flow (Fig. 2).
In five mice we tested the effect of 10 mg/kg furosemide
(Fig. 2). RBF fell from 1.67  0.25 to 0.69  0.14 ml/min at
5 min, a fall of 60.4  2% (P  0.05 vs. 2 mg/kg furosemide).
Arterial blood pressure before and 5 min after furosemide was
93.5  3 and 92.2  4.3 mmHg. Furosemide-induced urine
flow was 645  23 l/30 min, significantly higher than the
mean value of 398  40 l/30 min caused by 2 mg/kg
(P  0.01).
Candesartan. To assess a possible role of angiotensin II in
the furosemide-induced reduction of RBF, mice received an
intravenous injection of the AT1 receptor antagonist candesar-
tan (2 mg/kg). After a stabilization period of 20 min, the effect
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of furosemide on RBF was determined. Candesartan increased
RBF from 1.38  0.05 to 1.88  0.05 ml/min (37.4 
4.8%), and SBF from 364  21 to 408  23 PU (12.6 
2.9%), while arterial pressure fell by 22.8  2.4% from
93.0  4.0 to 71.9  4.1 mmHg (n  9, P  0.001 each).
Subsequent furosemide administration decreased both superfi-
cial and total renal blood flow, but the relative reductions were
significantly diminished in the presence of candesartan com-
pared with control (Fig. 3). The change of RVR caused by
furosemide, expressed as percent change integrated over time
(area under the curve, %change 	 time), averaged 2,563 
336 while the effect was reduced to 1,041  186 by cande-
sartan treatment (P  0.001; Fig. 4). While the difference in
total urine volume excreted during the course of the experiment
(30 min) did not reach significance between vehicle- and
candesartan-treated mice (398 40 vs. 286 29 l; n 8 vs.
n  5; P  0.073), peak urine flow was significantly reduced
after candesartan probably as a result of the blood pressure
reduction (15.8  1.9 vs. 25.6  2.3 l/min; P  0.01). The
efficiency of AT1 receptor blockade was verified at the end of
each experiment by determining the blood pressure response to
a bolus injection of angiotensin II (data not shown).
Indomethacin. Since furosemide is known to stimulate pros-
taglandin production, we tested the effect of furosemide fol-
lowing the administration of the nonspecific cyclooxygenase
(COX) inhibitor indomethacin (5 mg/kg). Furosemide reduced
RBF in indomethacin-treated mice from 1.2  0.17 ml/min to
a nadir of 0.78  0.11 ml/min (P  0.01; Fig. 3), a maximum
decrease by 35.2  0.3%. Arterial blood pressure of 92  9
mmHg was not significantly altered by furosemide. The time-
Fig. 1. Representative original recording of arterial blood pressure (top), superficial renal blood flow (SBF; middle), and total renal blood flow (RBF; bottom)
over a time period (x-axis) of 60 min after injection of furosemide (2 mg/kg body wt iv) in a wild-type mouse.
Fig. 2. Time course of total RBF and SBF (A), renal vascular resistance (RVR) and superficial vascular resistance (SVR; B), and mean arterial pressure (MAP)
and urine flow (C) after intravenous administration of furosemide (furo; 2 mg/kg body wt) in wild-type mice (RBF, RVR: n  8; SBF, SVR: n  6). RBF and
RVR time courses are also shown for the effect of 10 mg/kg furosemide (n  5).
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integrated relative reductions of RBF and the increase in RVR
were significantly less than in control mice (605  82 vs.
2,563  336; P  0.001; Fig. 4). Peak urine flow achieved by
furosemide in indomethacin-treated mice was significantly
reduced compared with control animals (15.7 4.3 vs. 25.6
2.3 l/min; P  0.05).
Decapsulation. To determine whether kidney hypoperfusion
after furosemide may be related to changes in tissue hydrostatic
pressure resulting from increased urine flow, RBF in response
to furosemide was determined after removal of the kidney
capsule (decapsulation) with and without concomitant AT1
receptor blockade. Removal of the kidney capsule did not
change baseline RBF (1.54  0.07 vs. 1.61  0.09 ml/min,
P  0.11) or arterial blood pressure (83  2.7 vs. 82  2.9
mmHg, P 0.32). However, SBF increased slightly (393 31
vs. 458  29 PU, P  0.011, n  6 each). After decapsulation
furosemide reduced RBF and SBF by 36.9  3.3 and 26.3 
5.1% after 4 min (n  5), respectively. Application of cande-
sartan following decapsulation further attenuated the effect of
furosemide on RBF (RBF decrease by 21.9  4.0% and SBF
decrease by 15.9  5.0% after 10 min, n  4) with the
furosemide-dependent decrease in RBF being significantly less
compared with decapsulation alone. The time-integrated in-
crease of RVR was reduced to 923 173 by decapsulation and
to 358  42 by decapsulation and candesartan (Fig. 4). Dif-
ferences in total urine excretion over 30 min did not reach
significance levels of 5% (decapsulation: 368  42 l, P 
0.63 vs. WT; decapsulation  candesartan: 279  53 l, P 
0.11 vs. WT, P  0.22 vs. decapsulation).
Free-flow proximal tubular pressure. Following furosemide
free-flow proximal tubular pressure (PFF) increased from
16.3  0.8 mmHg (n  15) to 40.0  4.3 mmHg (n  8;
Fig. 5) within 1–2 min, a total increase of 146% (P  0.001)
accompanied by a macroscopic swelling of the kidney. Re-
moval of the kidney capsule resulted in a significant decrease
in PFF to 11.7  0.8 mmHg (n  14, P  0.001 vs. control),
and a reduced PFF increase following furosemide injection to
29.0  2.8 mmHg (149%, n  10, P  0.001). During the
Table 1. Maximum percent changes at corresponding time points in total RVR and SVR
RVR SVR
Max. increase, % Time, min Max. increase, % Time, min
Control n  6–8 123.311.6 8.41.4 52.46.2 9.72.7
Candesartan n  5 62.712.1† 4.61.4 36.29.1 2.60.4*
Decapsulation n  5 67.313.2* 4.81.4 47.18.0 3.20.7
Candesartan  decapsulation n  4 26.64.0† 6.82.0 20.96.1 3.00.7
Indomethacin n  4 54.26.1† 3.20.6*
Maximum (max.) percent changes (means  SE) at corresponding time points (means  SE) in total renal vascular resistance (RVR) and superficial vascular
resistance (SVR) after 2 mg/kg iv furosemide (control), after pretreatment with the AT1-receptor antagonist candesartan (2 mg/kg iv), after removal of the kidney
capsule (decapsulation), or after 5 mg/kg indomethacin are shown. *P  0.05, †P  0.01 vs. control.
Fig. 3. Time course of total RBF (A), SBF (B),
MAP (C), and urine flow (D) after intravenous
administration of 2 mg/kg furosemide in wild-
type mice (control, n  6–8), following intra-
venous pretreatment with candesartan (2 mg/kg,
n  5) or indomethacin (5 mg/kg, n  4),
pretreatment by removal of the kidney capsule
(decapsulation, n  5) or both (decapsulation 
candesartan, n  4). Initial RBF or SBF values
at time 0 were not significantly different from
control in any of the experimental groups when
tested by 1-way ANOVA and Bonferroni post
hoc test.
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course of these experiments, arterial blood pressure dropped
significantly in both groups (control: 91.4  1.9 to 76.5  5.6
mmHg after 21–25 min, P  0.01; decapsulation: 86.3  1.9
to 78.8  1.0 mmHg, after 16–20 min, P  0.01). Free-flow
proximal tubular pressures in both groups returned to baseline
after 26–30 min (Fig. 5).
NKCC1-deficient mice. To explore whether the effect of
furosemide on RBF in vivo is modified by inhibition of
NKCC1, we examined the hemodynamic effect of furosemide
in NKCC1-deficient mice (n  5). Like in wild-type controls,
RBF and SBF decreased rapidly in NKCC1/ mice with
maximum decreases after 5 min averaging 45.4  4.6% (from
1.37  0.12 to 0.76  0.09 ml/min) for RBF (P  0.32) and
28.8  3.7% (from 347  11 to 246  14 PU) for SBF
(P 0.51, n 6) as shown in Fig. 6. No differences between
genotypes were found in arterial blood pressure, total urine
excretion after 30 min (NKCC1/: 389  50 l,
NKCC1/: 370  42 l, P  0.78), or the relative
changes and duration of the observed blood flow decrease
after furosemide injection.
Isolated perfused afferent arterioles. To assess the direct
vascular effects of furosemide, we determined the response of
isolated perfused afferent arterioles to bath application of the
drug. Experiments were performed in arterioles preconstricted
with 0.5 nM angiotensin II in the bath solution causing a vessel
diameter reduction from 8.8  0.4 to 4.2  0.5 m (P  0.05;
Fig. 7A). Furosemide applied in three doses over a total
observation time of 10 min induced a dose-dependent vasodi-
latation of the vessels (4.8  0.6, 5.9  0.5, and 7.8  0.6 for
30 mol/l, 300 mol/l, and 1.5 mmol/l of furosemide, respec-
tively, n 11). Figure 7B shows representative photographs of
the furosemide-mediated dilatation in a mouse-perfused arte-
riole. Vasodilatation was not the result of loss of angiotensin-
mediated constriction since time control experiments showed
that vessel constriction caused by angiotensin without furo-
semide was maintained throughout a 10-min application period
with no significant changes in diameter (5.8  0.7, 5.5  0.5,
and 5.5  0.6 m, 3, 5, and 10 min, respectively). To verify
the role of NKCC1 in afferent arteriolar vasodilatation, exper-
iments were repeated in vessels dissected from kidneys of
NKCC1-deficient mice. Like in vessels from wild-type mice,
angiotensin II (0.5 nM) reduced the diameter of afferent
arterioles (from 9.4  0.5 to 5.1  0.4 m), but in contrast to
wild-type arterioles, addition of furosemide to the bath at
increasing concentrations (30 M, 300 M, 1.5 mM) did not
alter afferent arteriole diameter of afferent arterioles of
NKCC1/ mice (5.1  0.5, 4.9  0.5, and 5.9  0.4 m at
30 mol/l, 300 mol/l, and 1.5 mmol/l, respectively, n  7;
Fig. 7A).
To address the question whether the vasodilatory effect of
furosemide is dependent on the mode of preconstriction, we
Fig. 4. Relative time-integrated changes of total RBF, SBF, RVR, and SVR
caused by furosemide (F) alone (2 or 10 mg/kg), and by furosemide under
conditions of candesartan (2 mg/kg; n  5) or indomethacin pretreatment (5
mg/kg; n 4), of decapsulation (n 5), and of decapsulation plus candesartan
(n  4). Bars indicate mean areas under the curve (%change 	 30 min)  SE.
n.d., Not determined. *P  0.05, **P  0.01 vs. F (2 mg/kg). #P  0.05 vs.
F  decapsulation.
Fig. 5. Time course of free-flow proximal tubular pressure (PFF;
bars) and MAP (symbols) after intravenous administration of 2
mg/kg furosemide in wild-type mice with (decapsulation, n  4)
or without (control, n  5) removal of the kidney capsule.
Numbers in columns represent the number of punctured tubules
before (baseline) and after furosemide application during indicated
time periods. *P  0.05, **P  0.01 vs. control.
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tested in an additional set of experiments the effect of
furosemide after inhibition of NOS activity by L-NAME.
L-NAME application to afferent arterioles of wild-type mice
decreased the diameter of the specimen (n  4) from 8.5 
0.6 to 5.5  0.6 m (P  0.05). Subsequent administration
of furosemide induced a significant increase in the luminal
diameter of the vessel averaging 8.6  1.0 m (58.7 
20.4%).
Fig. 6. Time course of total RBF (A), SBF (B), MAP
(C), and urine flow (D) after intravenous administration
of 2 mg/kg furosemide in NKCC1/ (n  5) and
NKCC1/ (n  6) mice.
Fig. 7. A: effect of furosemide on inner luminal diameter
of isolated perfused afferent arterioles from NKCC1/
(n  11) and NKCC1/ (n  7) mice. Arterioles were
preconstricted with angiotensin II. *P  0.05 vs. basal.

P  0.05 vs. angiotensin II. B: images of a perfused
afferent arteriole from a NKCC1 wild-type mouse under
resting conditions (Basal) and during bath addition of
angiotensin II (0.5 nM) and furosemide (30 M,
300 M). C: effect of 1.5 mM furosemide on inner
vascular diameter of perfused afferent arterioles from
NKCC1/ mice (n  4) after preconstriction with 50
M NG-nitro-L-arginine methyl ester (L-NAME). *P 
0.05 vs. basal.
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DISCUSSION
Despite numerous previous investigations, the effects of
loop diuretics on RVR have remained an issue of contention. In
view of the clinical importance of this class of drugs and their
use as an experimental tool, it would be desirable to arrive at
a better understanding of the principles that may underlie the
response of the renal vasculature to loop diuretics and to an
increase in urine flow in general. The present study was
therefore performed in mice to reinvestigate the effect of the
loop diuretic furosemide on RVR. Our data show that furo-
semide caused a vasodilatation of isolated perfused afferent
arterioles resulting from inhibition of NKCC1. Despite the
vasodilator potential of furosemide in vitro, we found a robust
and dose-dependent reduction in total and superficial renal
blood flow in the in situ kidney that was fast in onset and
occurred well before any decrements in mean arterial blood
pressure were observed. The in vivo studies are in qualitative
agreement with several previous results in rats that have shown
a consistent increase in RVR in response to furosemide (6, 15,
31). There is evidence that furosemide causes a preferential
reduction of medullary blood flow by 30% while cortical
blood flow fell by only 10% (6, 7). The present data in the
mouse are in agreement with the possibility of a more pro-
nounced reduction of medullary blood flow since the relative
change of total RBF was markedly greater than that of the
superficial cortex. Nevertheless, the magnitude of the reduction
of total RBF indicates that furosemide elevates vascular resis-
tance throughout the entire vascular bed of the mouse kidney.
We acknowledge that for unknown reasons, the observation of
an RBF reducing effect of furosemide has not been made in all
rat studies (17, 41). Overall, our and previous observations
suggest a species-specific response of RBF to furosemide, with
renal resistance increases being greater in mice than in rats and
absent in humans and dogs.
The markedly different hemodynamic responses to loop
diuretics in humans and dogs on the one hand and rats and mice
on the other are unlikely to be related to differences in the
inhibitory interactions of the diuretic with NKCC cotransporters.
There are no discernible differences in the efficacy of loop
diuretics to inhibit NKCC2 as judged from comparable diuretic
potencies of these agents across species. Furthermore, loop
diuretics have been shown to cause inhibition of TGF in both
dogs and rats (25, 40). Thus it is highly unlikely that the
different hemodynamic responses to furosemide in these spe-
cies reflect a difference in diuretic-induced TGF inhibition and
vasodilatation. Finally, direct vasodilator actions of loop di-
uretics have previously been observed in various blood vessels
of a number of species including humans, dogs, rabbits, and
rats (8). The current studies confirm that furosemide can cause
relaxation of isolated perfused afferent arterioles of the mouse
preconstricted with angiotensin II. Like in other studies of the
in vitro effect of furosemide on vascular tone, relatively high
concentrations of furosemide were required to observe dilator
effects (for reference, see Ref. 8). The causes for the relative
insensitivity of excised vessels to furosemide are unclear but
may reflect changes in basal variables such as the membrane
potential or absence of vasoactive cofactors. Since a dilator
effect was not seen in arterioles dissected from NKCC1-
deficient mice, relaxation appears to be due to inhibition of the
widely expressed NKCC1 isoform of the cotransporter. This
direct demonstration of a role for NKCC1 in vascular effects
confirms earlier notions based on isoform expression patterns
that the vascular actions of loop diuretics are caused by
NKCC1 inhibition (1). Nevertheless, a direct NKCC1-depen-
dent vasodilatation is unlikely to modify the in vivo response
of the renal vasculature to furosemide to a significant extent
since the increase in RVR was not augmented in NKCC1-
deficient compared with wild-type mice.
The mechanism by which NKCC1 inhibition leads to a
vasodilatation of afferent arterioles was not addressed in the
present study. However, recent patch-clamp studies in juxta-
glomerular cells of the afferent arteriole have shown that
furosemide induced an increase in an outward current that was
carried by potassium and caused marked cell hyperpolarization
(3). Alternatively or additionally, a decreased intracellular Cl
concentration after inhibition of NKCC1-dependent chloride
transport by furosemide might either inhibit voltage-dependent
calcium channels directly (27) or indirectly by driving HCO3
out of the cell via the Cl/HCO3 exchanger (42). In either
case, the result would be a reduction in cytosolic Ca2 in
smooth muscle cells of the afferent arteriole leading to a
decrease in vascular tone. Vascular dilatation by furosemide
was also suggested to be in part mediated by endothelium-
dependent generation of NO (33). For the afferent arteriole of
the mouse, however, this mechanism does not seem to be of
major relevance, since vessels preconstricted by application
of the NOS inhibitor L-NAME showed an unaltered dilatory
response upon addition of furosemide. This is in agreement
with the observation that maximal inhibition of the myo-
genic response by the diuretic bumetanide was independent
of NOS blockade by L-NAME, although the time course of
the vasodilatation was changed (37).
Administration of loop diuretics leads to a rapid increase in
renin secretion, an effect that is at least in part mediated by
inhibition of NKCC2 in the macula densa segment of the TAL
(3). Our experiments using the AT1 receptor antagonist can-
desartan suggest that angiotensin-dependent vasoconstriction
may contribute to the fall in RBF observed after furosemide
Fig. 8. Relationship between furosemide-induced urine flow (l/30 min) and
the relative time-integrated change of renal blood flow (%change 	 30 min)
for the different experimental conditions studied. The line indicates the linear
regression function.
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infusion, a finding which is in agreement with previous studies
in the rat (15). This mechanism would be consistent with the
dilator action of furosemide in vitro in that angiotensin-medi-
ated resistance changes may not be detectable in the in vitro-
perfused arteriole since the generation of angiotensin II and the
exposure of the vessel to sufficiently high angiotensin concen-
trations are unlikely to occur in this setting. Since infusion of
angiotensin II in control experiments suggested a rather com-
plete blockade of angiotensin receptors by candesartan, addi-
tional mechanisms must contribute to the decrease of RBF after
furosemide infusion.
Numerous studies have confirmed the original observation
that stimulation of prostaglandin production is another conse-
quence of furosemide administration (38). This effect is at least
in part the direct result of inhibition of NKCC2 in TAL cells
and subsequent stimulation of COX-2 activity (4, 23). Our
observations indicate that the increase in RVR caused by
furosemide is diminished following indomethacin. This finding
suggests that furosemide may lead to the release of a vasocon-
strictor prostaglandin, perhaps as a consequence of the in-
creased pelvic pressure associated with the increased urine
production (21, 24). It is possible that the magnified decrease
of RBF in the mouse is caused by the direct effect of a more
vasoconstrictive PG spectrum, although the effect of furo-
semide on urinary prostaglandin excretion appears to be a
generalized activation of prostaglandin synthesis across differ-
ent species (5, 18).
In view of absence of discernible species-specific differ-
ences in the response of the renin and prostaglandin systems to
furosemide, differential vascular responses to these agents may
not be an entirely satisfying explanation for the divergent
hemodynamic effects in different species. An analysis of our
data shows that there is a good correlation between furo-
semide-induced urine flow and the reduction of RBF (Fig. 8).
Although we are aware of the limitations of such correlations,
one may interpret this finding as indicating an influence of
urine flow per se on RBF. The underlying mechanism could be
a compression of peritubular capillaries by the abrupt rise in
tubular pressure. Several arguments could be made in favor of
such a scenario. First, this mechanism would be effective
independent of any direct or indirect vasomotor responses of
vascular smooth muscle cells and would therefore be compat-
ible with loop diuretics being vasodilator in nature. Second, the
blood flow reduction caused by furosemide was significantly
less after decapsulation, and this was associated with a lesser
increase of proximal tubular pressure. Third, the precipitous
early fall of RBF coincides with the prompt rise in tubular
pressure suggesting that the abrupt addition of nonabsorbed
tubular fluid cannot be accommodated by the major urinary
flow resistance in the collecting ducts in the early phase
consistent with the observation that the rise of tubule pressure
precedes the onset of a marked diuresis by several minutes.
Fourth, compression of peritubular capillaries following furo-
semide has recently been directly observed by two-photon
fluorescence microscopy of the kidney surface of rats (19).
Fifth, the effect of increased tubular pressure to compress
peritubular capillaries may well be a function of the size of the
kidney and may therefore represent the factor that differs
between mice and larger species. It is noteworthy that the
number of nephrons per unit kidney weight is four to five times
higher in mice than it is in humans. It would therefore seem
possible that an expansion of swollen tubules into the intersti-
tium without encroaching on capillary space may occur in
larger kidneys, but may not be possible in the more tightly
packed rat and mouse kidneys. In fact, furosemide has been
found to increase proximal tubule pressure in dogs, but this
was not accompanied by an increase in interstitial pressure, and
therefore probably not with capillary compression (20). It is
also possible that the urinary flow resistance is lower in
humans and dogs compared with rats or mice and that this
would permit an increase in urine flow without increasing
proximal pressure and volumes to a similar extent. This is
somewhat supported by the greater increase in proximal tubule
pressure in our study compared with an earlier observation in
dogs (20). Sixth, a remarkable vulnerability of the renal papilla
has been observed in numerous mouse models in which urine
flow is chronically elevated regardless of the cause of the
diuresis (22, 29, 36, 43). This papillary and medullary atrophy
appears to be a distinct feature of the mouse since Brattleboro
rats do not show a comparable phenotype (2), and it may be the
end result of a diuresis-induced impairment of the renal circu-
lation that is specific for the mouse kidney.
In summary, we found marked reductions of total and
superficial renal blood flow after furosemide administration in
anesthetized mice despite the fact that furosemide caused
vasodilatation of microperfused preconstricted afferent arte-
rioles through inhibition of NKCC1. The reduced RBF-lower-
ing effect of furosemide by candesartan or indomethacin treat-
ment indicates that the generation of angiotensin II and of a
vasoconstrictor prostaglandin may contribute to the increased
RVR caused by the diuretic. In addition, compression of
peritubular capillaries by the expanding tubular compartment
may contribute to the impairment of blood flow by furosemide.
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